Endocrinology

Diagnosis and Understanding Your Tests

At a Glance

Panhypophysitis cannot be confirmed by MRI alone. Doctors combine the scan with morning cortisol and other pituitary hormone tests, symptoms, treatment history, and sometimes visual-field testing or biopsy to distinguish inflammation from tumors or cancer spread.

Because panhypophysitis is so rare, the diagnostic process is like solving a complex puzzle. Your care team must distinguish between an inflammatory condition, a common pituitary tumor, a metastasis, and other potential causes using a combination of detailed imaging and precise hormonal mapping ^[1]^[2].

Reading Your MRI: Clues of Inflammation

When a doctor looks at an MRI of a pituitary with panhypophysitis, they aren’t just looking for enlargement; they are looking for a specific pattern of swelling. While a pituitary adenoma (a benign tumor) usually looks like a distinct, localized “lump,” panhypophysitis typically causes a more uniform change ^[3]^[2].

Key features that suggest panhypophysitis include:

Symmetric Enlargement: The entire gland swells evenly, often taking on a “dumbbell” or “triangular” shape ^[1]^[4].
Thickened Stalk: The infundibulum (the stalk connecting the gland to the brain) often becomes significantly wider but remains centered ^[1]^[5].
Loss of the “Bright Spot”: On a normal T1-weighted MRI, the back of the pituitary normally shows up as a bright spot. In panhypophysitis, this spot often disappears, which is a clue pointing toward inflammation ^[1]^[6].
Intense Enhancement: When contrast dye is used, the inflamed area often “lights up” brightly and uniformly ^[1]^[7].

Important Caveat: These findings are suggestive, not proof. They overlap with adenomas, metastases (cancer spread), infections, and cysts. An MRI alone cannot definitively rule out these mimics. Diagnosis integrates your clinical history, serial imaging, hormone tests, and sometimes a formal visual-field assessment by an ophthalmologist.

What Happens Next?

The diagnostic sequence usually follows this path: a review of your medication and oncology history, comprehensive pituitary hormone testing, visual-field assessment when indicated, MRI review, careful exclusion of mimics (like infections or cancer spread), and planning follow-up.

The Endocrine Checklist

Blood and urine tests are the only way to “see” how well your pituitary is actually working. A complete evaluation should include a full panel ^[8]^[9]:

Axis / System	Essential Tests	Safeguards & Notes
Stress Response	Morning Cortisol and ACTH	Cortisol and ACTH are affected by taking glucocorticoids. Never skip or hold your prescribed hydrocortisone on your own for a test. ^[8]
Thyroid	Free T4 and TSH	TSH alone cannot guide treatment for central hypothyroidism; free T4 is central to the diagnosis ^[8].
Growth/Metabolism	IGF-1	This is a screening test and does not by itself diagnose or exclude growth hormone deficiency ^[8]^[10].
Reproduction	LH, FSH, Testosterone/Estradiol	Evaluation for central hypogonadism ^[8]^[11].
Milk Production	Prolactin	Checked to assess stalk compression ^[8].
Water Balance	Sodium, Serum/Urine Osmolality	Thirst alone is not enough; diagnosis requires documented urine volume and specialist-directed paired testing ^[12].

If your morning blood tests are borderline, your doctor may order dynamic testing, such as the cosyntropin (Synacthen) stimulation test ^[13]^[14]. However, note that this test can be falsely reassuring in early central adrenal insufficiency.

The “Normal MRI” Trap in Immunotherapy

If you are taking an immune checkpoint inhibitor (ICI) for cancer treatment, your diagnosis might rely entirely on blood work. In many cases—especially with PD-1 or PD-L1 inhibitors—the pituitary can be severely damaged and stop producing ACTH even while appearing completely normal on an MRI ^[15]^[16]. If you have symptoms like extreme fatigue or nausea while on these medications, a normal MRI does not mean your pituitary is healthy; blood tests for cortisol and ACTH are the true diagnostic tools ^[17]^[18].

When is a Biopsy Necessary?

A pituitary biopsy involves a neurosurgeon taking a tiny sample of the gland’s tissue ^[19]. Because this carries risks, it is rarely the first step ^[20]^[21].

A biopsy is generally only considered if ^[19]^[22]:

The Diagnosis is Uncertain: Your doctors cannot tell if the mass is inflammation, a tumor, or a metastasis.
Vision is Threatened: The swelling is pressing so hard on your optic nerves that your sight is rapidly declining, requiring urgent surgical decompression.
Treatment Fails: The inflammation does not respond to therapies as expected.

Common questions in this guide

How is panhypophysitis diagnosed?

Doctors combine your symptoms and medical history with pituitary hormone tests and a detailed MRI review. Visual-field testing may be needed, and a biopsy is reserved for situations where the diagnosis remains uncertain, vision is threatened, or treatment does not work as expected.

What MRI findings can suggest panhypophysitis?

Possible clues include even enlargement of the pituitary, a thickened but centered stalk, loss of the normal bright spot at the back of the gland, and strong uniform enhancement after contrast. These findings can also occur with tumors, cancer spread, infection, or cysts, so an MRI cannot confirm the diagnosis by itself.

Which blood tests are used to check pituitary function?

Testing may include morning cortisol and ACTH, free T4 and TSH, IGF-1, LH and FSH with testosterone or estradiol, prolactin, sodium, and blood and urine concentration measurements. Free T4 is especially important when checking for low thyroid function caused by a pituitary problem, because TSH alone may be misleading.

Can immunotherapy-related pituitary inflammation occur with a normal MRI?

Yes. People receiving PD-1 or PD-L1 immune checkpoint inhibitors can develop serious loss of ACTH production even when the pituitary looks normal on MRI. Symptoms such as severe fatigue or nausea should prompt medical review and blood testing for cortisol and ACTH.

What happens if my morning cortisol result is borderline?

Your doctor may order a cosyntropin, also called Synacthen, stimulation test to assess adrenal function. In early pituitary-related adrenal insufficiency, this test can sometimes appear reassuring, so results must be interpreted with your symptoms, timing, medications, and other hormone tests.

When is a pituitary biopsy considered?

A biopsy is uncommon because it carries risks and is usually not the first diagnostic step. It may be considered when doctors cannot distinguish inflammation from a tumor or cancer spread, when swelling is rapidly threatening vision, or when the condition does not respond as expected to treatment.

Curated prompts to bring to your next appointment.

1.Does my MRI show specific signs like a 'dumbbell' shape or a thickened stalk that point toward inflammation rather than a tumor or metastasis?
2.In my recent blood tests, were my morning cortisol and ACTH levels both low, or were they borderline enough to need a stimulation test?
3.When interpreting my thyroid labs, are we looking at my free T4 levels rather than just the TSH?
4.Do I need a formal visual-field assessment by an ophthalmologist?
5.If you are recommending a biopsy, what specific information are we looking for that my blood tests and MRI haven't already provided?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

MRI clues include symmetric pituitary enlargement, a thickened centered stalk, loss of the posterior bright spot, and uniform contrast enhancement, but these findings are not diagnostic alone.
A complete evaluation may check morning cortisol and ACTH, free T4 and TSH, IGF-1, reproductive hormones, prolactin, sodium, and osmolality.
Serious ACTH deficiency can develop during PD-1 or PD-L1 immunotherapy even when the pituitary appears normal on MRI.
A cosyntropin stimulation test may be used for borderline morning cortisol, although early pituitary-related adrenal insufficiency can produce a reassuring result.
Pituitary biopsy is rarely a first-line test and is mainly considered when the diagnosis remains uncertain, vision is threatened, or expected treatment response does not occur.

References (22)

1
Clinical presentation and magnetic resonance imaging characteristics of lymphocytic hypophysitis: a systematic review with meta-analysis.
Ju JS, Cui T, Zhao J, et al.
Archives of medical science : AMS 2023; (19(4)):976-986 doi:10.5114/aoms/144628.
PMID: 37560735
2
Imaging findings in hypophysitis: a review.
Caranci F, Leone G, Ponsiglione A, et al.
La Radiologia medica 2020; (125(3)):319-328 doi:10.1007/s11547-019-01120-x.
PMID: 31863360
3
Clinical and hormonal characteristics of patients with different types of hypophysitis: a single-center experience.
Imga NN, Yildirim AE, Baser OO, Berker D
Archives of endocrinology and metabolism 2019; (63(1)):47-52 doi:10.20945/2359-3997000000102.
PMID: 30864631
4
Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease.
Langlois F, Varlamov EV, Fleseriu M
The Journal of clinical endocrinology and metabolism 2022; (107(1)):10-28 doi:10.1210/clinem/dgab672.
PMID: 34528683
5
Primary lymphocytic hypophysitis: Clinical characteristics and treatment of 50 cases in a single centre in China over 18 years.
Wang S, Wang L, Yao Y, et al.
Clinical endocrinology 2017; (87(2)):177-184 doi:10.1111/cen.13354.
PMID: 28423475
6
Diabetes insipidus secondary to sellar/parasellar lesions.
Angelousi A, Mytareli C, Xekouki P, et al.
Journal of neuroendocrinology 2021; (33(3)):e12954 doi:10.1111/jne.12954.
PMID: 33769630
7
[Clinical features and prognosis of 18 cases of primary lymphocytic hypophysitis].
Wei Q, Yang GQ, Li YJ, et al.
Zhonghua yi xue za zhi 2018; (98(2)):102-108 doi:10.3760/cma.j.issn.0376-2491.2018.02.006.
PMID: 29343033
8
Hypopituitarism.
Higham CE, Johannsson G, Shalet SM
Lancet (London, England) 2016; (388(10058)):2403-2415 doi:10.1016/S0140-6736(16)30053-8.
PMID: 27041067
9
Congenital Hypopituitarism.
Parks JS
Clinics in perinatology 2018; (45(1)):75-91 doi:10.1016/j.clp.2017.11.001.
PMID: 29406008
10
Utility of serum IGF-1 for diagnosis of growth hormone deficiency following traumatic brain injury and sport-related concussion.
Lithgow K, Chin A, Debert CT, Kline GA
BMC endocrine disorders 2018; (18(1)):20 doi:10.1186/s12902-018-0247-1.
PMID: 29609574
11
Approach to the Patient: A Case With an Unusual Cause of Hypopituitarism.
Das L, Dutta P
The Journal of clinical endocrinology and metabolism 2023; (108(6)):1488-1504 doi:10.1210/clinem/dgac747.
PMID: 36573291
12
Causes and Follow-Up of Central Diabetes Insipidus in Children.
Liu W, Hou J, Liu X, et al.
International journal of endocrinology 2019; (2019()):5303765 doi:10.1155/2019/5303765.
PMID: 31049061
13
Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.
Suzuki S, Ruike Y, Ishiwata K, et al.
Journal of the Endocrine Society 2022; (6(8)):bvac088 doi:10.1210/jendso/bvac088.
PMID: 35795807
14
Normal adrenocorticotropic hormone levels do not exclude adrenal insufficiency during immune checkpoint inhibitor therapy: evidence from clinical, steroid, and structural analyses.
Ishibashi Y, Baba R, Okada A, et al.
Frontiers in endocrinology 2025; (16()):1683546 doi:10.3389/fendo.2025.1683546.
PMID: 41189622
15
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.
Quandt Z, Kim S, Villanueva-Meyer J, et al.
Journal of the Endocrine Society 2023; (7(4)):bvad012 doi:10.1210/jendso/bvad012.
PMID: 36860908
16
Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up.
Levy M, Abeillon J, Dalle S, et al.
Journal of clinical medicine 2020; (9(10)) doi:10.3390/jcm9103280.
PMID: 33066179
17
[Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC, Liu Y, Xie C, Cao BS
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2022; (54(2)):369-375.
PMID: 35435206
18
Magnetic resonance imaging features of hypophysitis in patients with cancer treated with immune checkpoint inhibitors.
Angelousi A, Asimakopoulou S, Bourgioti C, et al.
Journal of neuroendocrinology 2026; (38(1)):e70116 doi:10.1111/jne.70116.
PMID: 41243162
19
Clinical Features, Magnetic Resonance Imaging, and Treatment Experience of 20 Patients with Lymphocytic Hypophysitis in a Single Center.
Zhu Q, Qian K, Jia G, et al.
World neurosurgery 2019; (127()):e22-e29 doi:10.1016/j.wneu.2019.01.250.
PMID: 30790734
20
Pituitary Stalk Lesion Sampling by Transsphenoidal Posterior Lobe Biopsy: A Case Series.
Hiatt K, Abecassis ZA, Eaton J, et al.
Journal of neurological surgery. Part B, Skull base 2026; (87(3)):308-313 doi:10.1055/a-2620-3407.
PMID: 42095031
21
Delayed Vasospasm in Endoscopic Transsphenoidal Pituitary Surgery: Two Case Reports and Reviews.
S Birua GJ, Tyagi G, Beniwal M, et al.
Neurology India 2022; (70(3)):996-1003 doi:10.4103/0028-3886.349613.
PMID: 35864631
22
The management of hypophysitis.
Karaca Z, Kelestimur F
Minerva endocrinologica 2016; (41(3)):390-9.
PMID: 26963662

This page is for informational purposes only and does not constitute medical advice. Your endocrinologist and care team should interpret your panhypophysitis tests and decide whether further evaluation is needed.

Get notified when new evidence is published on Panhypophysitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents